Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »
Jul 29, 2014

Epigenetic Biomarkers and Clinical Trials

This report presents a snapshot of the epigenetic landscape as it is today.

Epigenetic Biomarkers and Clinical Trials

Epigenetics is currently an amorphous discipline, but there is a definite push toward development and commercialization of diagnostics and therapeutics. [Kenneth Eward/BioGrafx/Photo Researchers]

  • The focus of this GEN Market & Tech Analysis report is to present some of our recent industry tracking of the epigenetics clinical trials and biomarker signatures space.

    Highlights of this report:

    • The epigenetics space represents a rich source of biomarkers and potential therapeutics since the target of action (chromatin) is highly proximal to the site of gene expression.
    • DNA is highly stable ex vivo and offers an excellent starting material for the development of prognostic or predictive biomarker-based tests (potential for epigenetics-based clinical diagnostics development).
    • Clinical trials in the epigenetics space are 50% focused on various cancer classes—indeed this represents the role of cancer as key driver of the epigenetic field, and the current FDA-approved epigenetics-based drugs target various cancer classes.
    • Even though epigenetics is an “amorphous space” we believe that, from a diagnostics and therapeutics perspective, we cannot discount its potential given strong drivers in its favor.
    • Beyond cancer, another area where epigenetics modifications are gaining increasing interest are in the CNS, where epigenetics changes may underlie learning, memory, etc.

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »